pSivida

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "PSivida" – news · newspapers · books · scholar · JSTOR (March 2020) (Learn how and when to remove this template message)

EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) pSivida is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.

pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ).^{[citation needed]} QinetiQ continues to be a strategic partner.^[1][2]

In June 2004, pSivida acquired full ownership of pSiMedica.^[1] In April 2018, pSivida purchased eye products firm Icon Bioscience.^[3][4]

See also[edit]

• Alimera Sciences, pSvida's partner on Iluvien

References[edit]

External links[edit]

• Official website
• "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. Retrieved May 15, 2015.
• Lindon, Hal (May 5, 2014). "UPDATE: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur". Benzinga. Retrieved May 15, 2015. pSivida's Dinesh K. Nadarassan presented a poster entitled "Sustained Release of Bevacizumab (Avastin) from BioSilicon"
• pSivida Mesoporous silicon patent

This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

• v
• t
• e